Yo spark wake up and stop heading soccer balls...LXXN check it out...
Lexon Announces Major Colon Cancer Breakthrough
TULSA, Okla., Sep 22, 1999 (BW HealthWire) -- Lexon, Inc. (OTC BB:
LXXN) today announced the development of a bioassay test for the ebaf
protein.
Lexon's Ebaf Assay(TM) prototype utilizes a standard bioassay system
available to most clinical laboratories. This bioassay form of the Ebaf
Assay(TM) actually measures the amount of biologically active ebaf
protein present. The bioassay can potentially be used not only to
detect the presence of ebaf, but also to quantitate the amount of ebaf
in cancer tissue and in the serum of cancer patients.
The ebaf protein appears in the blood of patients with colon cancer and
in some forms of ovarian and testicular cancer and detection of ebaf in
the blood can be used as a screening test. The ebaf protein can be
detected with complex laboratory equipment, and now with the newly
developed bioassay. Lexon will subsequently develop a test kit, so that
any clinical laboratory can screen blood for colon cancer. Lexon
believes that the test, once past the FDA approval process, will be
quick, inexpensive, and widely available.
Lexon has sponsored and funded the continuing research and development
of the cancer screening test at North Shore University Hospital in
Manhasset, New York, under the direction of Dr. Siamak Tabibzadeh, the
developer of the Ebaf Assay(TM). Dr. Tabibzadeh currently serves as
Chief of Experimental Pathology at North Shore. The completion of this
phase of the development allows for the initiation of preclinical
patient testing to gather data for the FDA approval process. Gifford
Mabie, President of Lexon, said, "We are gratified to have participated
in the development of the first and only blood test for the early
detection of colon cancer. This test is a major clinical innovation!"
|
